Last 12 months
Inside the activity.
0 purchase rows · 27 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 7 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 10 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2020 Filed Mar 12, 2020 20:20 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 142,000 | $0.00 Strike: $44.67 | $0.00 |
DisclosureSEC source: 0001209191-20-018493 · doc4.xml · derivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,000 Underlying: Common Shares · 142,000 shares Expires 2030-03-10 F1 · derivative.exercise_date: This option was granted on March 10, 2020 with respect to 142,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2020. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:20 UTC |
KASINGER JAMES R.General Counsel and Secretary
|
GrantRestricted Stock Units · Derivative | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-018492 · doc4.xml · derivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Shares · 8,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:20 UTC |
KASINGER JAMES R.General Counsel and Secretary
|
GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $44.67 | $0.00 |
DisclosureSEC source: 0001209191-20-018492 · doc4.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Shares · 35,000 shares Expires 2030-03-10 F1 · derivative.exercise_date: This option was granted on March 10, 2020 with respect to 35,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2020. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:20 UTC |
Ho Tony WExecutive VP, Head of R&D
|
GrantRestricted Stock Units · Derivative | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-018491 · doc4.xml · derivative · entry 2 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Shares · 13,750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2020 with respect to 13,750 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2020 with respect to 13,750 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:20 UTC |
Ho Tony WExecutive VP, Head of R&D
|
GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $44.67 | $0.00 |
DisclosureSEC source: 0001209191-20-018491 · doc4.xml · derivative · entry 1 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Shares · 55,000 shares Expires 2030-03-10 F1 · derivative.exercise_date: This option was granted on March 10, 2020 with respect to 55,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2020. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:10 UTC |
Klein Lawrence OttoCBO & COO
|
GrantRestricted Stock Units · Derivative | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-018468 · doc4.xml · derivative · entry 2 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Shares · 13,750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2020 with respect to 13,750 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2020 with respect to 13,750 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:10 UTC |
Klein Lawrence OttoCBO & COO
|
GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $44.67 | $0.00 |
DisclosureSEC source: 0001209191-20-018468 · doc4.xml · derivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Shares · 55,000 shares Expires 2030-03-10 F1 · derivative.exercise_date: This option was granted on March 10, 2020 with respect to 55,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2020. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:13 UTC |
Ho Tony WExecutive VP, Head of R&D
|
Tax withholdingCommon Shares | 1,563 | $52.64 | $82,276.32 |
DisclosureSEC source: 0001209191-20-017240 · doc4.xml · nonDerivative · entry 2 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,605 F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 20:13 UTC |
Ho Tony WExecutive VP, Head of R&D
|
Exercise / conversionCommon Shares | 3,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-017240 · doc4.xml · nonDerivative · entry 1 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On March 5, 2019, the reporting person was granted 10,000 restricted stock units. On March 5, 2020, 3,333 restricted stock units vested. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:26 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
Tax withholdingCommon Shares | 794 | $52.74 | $41,875.56 |
DisclosureSEC source: 0001209191-20-016085 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,526 F1 · kind: On December 1, 2017, the reporting person was granted 26,667 restricted stock units. On March 1, 2020, 1,667 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 21:05 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001209191-19-061091 · doc4.xml · derivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,058 Underlying: Common Shares · 8,000 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 21:05 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
Exercise / conversionCommon Shares | 8,000 | $1.81 | $14,480.00 |
DisclosureSEC source: 0001209191-19-061091 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:05 UTC |
TOMSICEK MICHAEL JOHNChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-059280 · doc4.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. F2 · derivative.expiration_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:05 UTC |
Klein Lawrence OttoChief Business Officer
|
GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-059281 · doc4.xml · derivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. F2 · derivative.expiration_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:05 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
GrantRestricted Stock Units · Derivative | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-059279 · doc4.xml · derivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Shares · 120,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. F2 · derivative.expiration_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:00 UTC |
Ho Tony WExecutive VP, Head of R&D
|
GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-059277 · doc4.xml · derivative · entry 1 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022 F2 · derivative.expiration_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022 Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:00 UTC |
KASINGER JAMES R.General Counsel and Secretary
|
GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-059276 · doc4.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. F2 · derivative.expiration_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. Read SEC document |
| December 01, 2019 Filed Dec 2, 2019 22:12 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
Tax withholdingCommon Shares | 741 | $71.65 | $53,092.65 |
DisclosureSEC source: 0001209191-19-058570 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,320 F1 · kind: On December 1, 2017, the reporting person was granted 26,667 restricted stock units. On December 1, 2019, 1,667 restricted stock units vested, and the reporting person forfeited 741 common shares to the issuer to satisfy tax withholding obligations. Read SEC document |
| November 19, 2019 Filed Nov 22, 2019 00:53 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 28,255 | $67.41 | $1,904,782.57 |
DisclosureSEC source: 0001209191-19-057685 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 596,741 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.35 to $73.75, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"). The Reporting Person is a managing member of VVM LLC and pursuant to agreement with VVM LLC, the Reporting Person is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein. Read SEC document |
| November 19, 2019 Filed Nov 22, 2019 00:53 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 13,745 | $67.41 | $926,605.43 |
DisclosureSEC source: 0001209191-19-057685 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.35 to $73.75, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:09 UTC |
Novak RodgerDirector · President
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 33,618 | $0.00 Strike: $14.43 | $0.00 |
DisclosureSEC source: 0001209191-19-057604 · doc4.xml · derivative · entry 3 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,382 Underlying: Common Shares · 33,618 shares Expires 2024-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 270,000 options to purchase common shares were granted on June 15, 2017 and originally vested in 48 equal monthly installments commencing upon the grant date. Pursuant to Dr. Novak's amended and restated employment agreement with the Company, subject to his continued employment, beginning November 30, 2018, the remaining unvested options from this grant vest in equal monthly installments at the rate of 50% of the amounts originally scheduled to vest on any one vesting date, and the original vesting schedule was extended to reflect the amended schedule. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:09 UTC |
Novak RodgerDirector · President
|
SaleCommon Shares | 33,618 | $70.00 | $2,353,260.00 |
DisclosureSEC source: 0001209191-19-057604 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:09 UTC |
Novak RodgerDirector · President
|
Exercise / conversionCommon Shares | 33,618 | $14.43 | $485,107.74 |
DisclosureSEC source: 0001209191-19-057604 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:07 UTC |
CAGNONI PABLO JDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001209191-19-057596 · doc4.xml · derivative · entry 3 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,833 Underlying: Common Shares · 7,500 shares Expires 2025-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:07 UTC |
CAGNONI PABLO JDirector
|
SaleCommon Shares | 7,500 | $62.00 | $465,000.00 |
DisclosureSEC source: 0001209191-19-057596 · doc4.xml · nonDerivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:07 UTC |
CAGNONI PABLO JDirector
|
Exercise / conversionCommon Shares | 7,500 | $5.59 | $41,925.00 |
DisclosureSEC source: 0001209191-19-057596 · doc4.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:30 UTC |
CAGNONI PABLO JDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001209191-19-056372 · doc4.xml · derivative · entry 3 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,333 Underlying: Common Shares · 7,500 shares Expires 2025-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter. Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:30 UTC |
CAGNONI PABLO JDirector
|
SaleCommon Shares | 7,500 | $55.00 | $412,500.00 |
DisclosureSEC source: 0001209191-19-056372 · doc4.xml · nonDerivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:30 UTC |
CAGNONI PABLO JDirector
|
Exercise / conversionCommon Shares | 7,500 | $5.59 | $41,925.00 |
DisclosureSEC source: 0001209191-19-056372 · doc4.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2019 Filed Nov 1, 2019 22:34 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 21,000 | $51.89 | $1,089,675.30 |
DisclosureSEC source: 0001209191-19-054773 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,745 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.73 to $52.11, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 30, 2019 Filed Nov 1, 2019 22:35 UTC |
CAGNONI PABLO JDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001209191-19-054774 · doc4.xml · derivative · entry 3 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,833 Underlying: Common Shares · 7,500 shares Expires 2025-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter. Read SEC document |
| October 30, 2019 Filed Nov 1, 2019 22:35 UTC |
CAGNONI PABLO JDirector
|
SaleCommon Shares | 7,500 | $52.00 | $390,000.00 |
DisclosureSEC source: 0001209191-19-054774 · doc4.xml · nonDerivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 30, 2019 Filed Nov 1, 2019 22:35 UTC |
CAGNONI PABLO JDirector
|
Exercise / conversionCommon Shares | 7,500 | $5.59 | $41,925.00 |
DisclosureSEC source: 0001209191-19-054774 · doc4.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 20:33 UTC |
KASINGER JAMES R.General Counsel and Secretary
|
GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-049322 · doc4.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: The restricted stock units shall vest in full on September 10, 2021, subject to continued employment with the company. F2 · derivative.expiration_date: The restricted stock units shall vest in full on September 10, 2021, subject to continued employment with the company. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 20:32 UTC |
Klein Lawrence OttoChief Business Officer
|
GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-049320 · doc4.xml · derivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: The restricted stock units shall vest in full on September 10, 2021, subject to continued employment with the company. F2 · derivative.expiration_date: The restricted stock units shall vest in full on September 10, 2021, subject to continued employment with the company. Read SEC document |
| September 01, 2019 Filed Sep 3, 2019 20:23 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
Tax withholdingCommon Shares | 740 | $46.21 | $34,195.40 |
DisclosureSEC source: 0001209191-19-047962 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,061 F1 · kind: On December 1, 2017, the reporting person was granted 26,667 restricted stock units. On September 1, 2019, 1,666 restricted stock units vested, and the reporting person forfeited 740 common shares to the issuer to satisfy tax withholding obligations. Read SEC document |
| August 02, 2019 Filed Aug 5, 2019 21:49 UTC |
Ho Tony WExecutive VP, Head of R&D
|
Tax withholdingCommon Shares | 14,534 | $52.56 | $763,907.04 |
DisclosureSEC source: 0001209191-19-044652 · doc4.xml · nonDerivative · entry 2 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,835 Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 21:49 UTC |
Ho Tony WExecutive VP, Head of R&D
|
Exercise / conversionRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-044652 · doc4.xml · derivative · entry 3 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: On August 1, 2017, the reporting person was granted 75,000 restricted stock units that vested in two equal annual installments on 8/1/2018 and 8/1/2019. F2 · derivative.expiration_date: On August 1, 2017, the reporting person was granted 75,000 restricted stock units that vested in two equal annual installments on 8/1/2018 and 8/1/2019. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 21:49 UTC |
Ho Tony WExecutive VP, Head of R&D
|
Exercise / conversionCommon Shares | 37,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-044652 · doc4.xml · nonDerivative · entry 1 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,369 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| July 11, 2019 Filed Jul 12, 2019 20:13 UTC |
Klein Lawrence OttoChief Business Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 8,421 | $0.00 Strike: $5.86 | $0.00 |
DisclosureSEC source: 0000899243-19-019535 · doc4.xml · derivative · entry 6 Klein Lawrence Otto · CIK 0001762583 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,666 Underlying: Common Shares · 8,421 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was granted an option to purchase 106,666 shares on March 2, 2016. 23,000 of such options were previously exercised, and the shares underlying those options were sold. 25% of this option became vested and fully exercisable on February 1, 2017, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the first day of each month thereafter. Read SEC document |
| July 11, 2019 Filed Jul 12, 2019 20:13 UTC |
Klein Lawrence OttoChief Business Officer
|
SaleCommon Shares | 8,421 | $50.01 | $421,171.26 |
DisclosureSEC source: 0000899243-19-019535 · doc4.xml · nonDerivative · entry 4 Klein Lawrence Otto · CIK 0001762583 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.1525, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 11, 2019 Filed Jul 12, 2019 20:13 UTC |
Klein Lawrence OttoChief Business Officer
|
Exercise / conversionCommon Shares | 8,421 | $5.86 | $49,347.06 |
DisclosureSEC source: 0000899243-19-019535 · doc4.xml · nonDerivative · entry 3 Klein Lawrence Otto · CIK 0001762583 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:13 UTC |
Klein Lawrence OttoChief Business Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 11,579 | $0.00 Strike: $5.86 | $0.00 |
DisclosureSEC source: 0000899243-19-019535 · doc4.xml · derivative · entry 5 Klein Lawrence Otto · CIK 0001762583 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,087 Underlying: Common Shares · 11,579 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was granted an option to purchase 106,666 shares on March 2, 2016. 23,000 of such options were previously exercised, and the shares underlying those options were sold. 25% of this option became vested and fully exercisable on February 1, 2017, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the first day of each month thereafter. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:13 UTC |
Klein Lawrence OttoChief Business Officer
|
SaleCommon Shares | 11,579 | $50.02 | $579,181.58 |
DisclosureSEC source: 0000899243-19-019535 · doc4.xml · nonDerivative · entry 2 Klein Lawrence Otto · CIK 0001762583 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.075, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:13 UTC |
Klein Lawrence OttoChief Business Officer
|
Exercise / conversionCommon Shares | 11,579 | $5.86 | $67,852.94 |
DisclosureSEC source: 0000899243-19-019535 · doc4.xml · nonDerivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:10 UTC |
Novak RodgerDirector · President
|
SaleCommon Shares | 50,000 | $50.00 | $2,500,065.00 |
DisclosureSEC source: 0000899243-19-019531 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 848,007 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.01, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 20:15 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-19-017420 · doc4.xml · derivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,058 Underlying: Common Shares · 20,000 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 20:15 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
SaleCommon Shares | 20,000 | $46.00 | $920,000.00 |
DisclosureSEC source: 0000899243-19-017420 · doc4.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,801 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.045, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 20:15 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
Exercise / conversionCommon Shares | 20,000 | $1.81 | $36,200.00 |
DisclosureSEC source: 0000899243-19-017420 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 21:05 UTC |
Greene JohnDirector
|
GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $43.52 | $0.00 |
DisclosureSEC source: 0000899243-19-016846 · doc4.xml · derivative · entry 1 Greene John · CIK 0001610732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: This option was granted on June 11, 2019 with respect to 30,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.